Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics


Madrigal Pharmaceuticals, Inc. (MDGL)

Today's Latest Price: $109.71 USD

0.00 (0.00%)

Updated Jan 20 6:55pm

Add MDGL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MDGL Stock Price Chart Interactive Chart >

Price chart for MDGL

MDGL Price/Volume Stats

Current price $109.71 52-week high $137.28
Prev. close $109.71 52-week low $56.82
Day low $107.00 Volume 187,600
Day high $110.60 Avg. volume 137,950
50-day MA $117.18 Dividend yield N/A
200-day MA $110.63 Market Cap 1.70B

Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio


Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.


MDGL Latest News Stream


Event/Time News Detail
Loading, please wait...

MDGL Latest Social Stream


Loading social stream, please wait...

View Full MDGL Social Stream

Latest MDGL News From Around the Web

Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.

B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com

B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Investing.com | January 12, 2021

Here's Why We're Not Too Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 24, 2020

Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc

Investing.com | November 12, 2020

Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights - Stocks News Feed

CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments. The Company also announced its third quarter 2020 financial results and highlights. The original target enrollment for MAESTRO… Read More »Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights

Stocks News Feed | November 5, 2020

The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halo...

Benzinga | November 5, 2020

Read More 'MDGL' Stories Here

MDGL Price Returns

1-mo -6.99%
3-mo -16.25%
6-mo 2.27%
1-year 32.10%
3-year -15.15%
5-year 1,206.07%
YTD -1.31%
2020 22.02%
2019 -19.17%
2018 22.80%
2017 516.04%
2016 21.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.852 seconds.